PCML
LEGN icon

Pavaki Capital Management LLC’s Legend Biotech LEGN Stock Holding History

Pavaki Capital Management LLC’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Hold
6,305
– – 0.06% 135
2026
Q1 		$114K Buy
6,305
+5
+0.1% +$95 0.05% 147
2025
Q4 		$137K Buy
+6,300
New +$180K 0.05% 120

Other funds holding LEGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
IAMH
IvyRock Asset Management (HK) Sheung Wan, Hong Kong $177M AUM 10.49% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pavaki Capital Management LLC's LEGN Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Legend Biotech (LEGN) position steady in Q2 2026 at 6,305 shares worth $182K. The position accounts for 0.06% of the portfolio, ranked #135.

Pavaki Capital Management LLC first reported a position in LEGN in Q4 2025 and has held it in 3 quarters since. 79 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Pavaki Capital Management LLC held 6,305 shares of Legend Biotech worth $182K as of Q2 2026.
  • Pavaki Capital Management LLC left its Legend Biotech share count unchanged in Q2 2026.
  • Legend Biotech made up 0.06% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #135 holding.
  • Pavaki Capital Management LLC first reported a position in Legend Biotech in Q4 2025 and has held it in 3 quarters since.
  • 79 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.